Issue 11, 2017

Design, synthesis and structure–activity relationships of (±)-isochaihulactone derivatives

Abstract

Z-K8 (2), the racemic form of isochaihulactone (1), previously showed significant antitumor effects in A549 and LNCaP tumor-bearing mice. In the present study, 17 derivatives of 2 were designed, synthesized and evaluated for their anti-proliferative activity against four human tumor cell lines. All new derivatives exhibited high potency against A549 and P-glycoprotein (P-gp)-overexpressing KB-VIN. One of our new derivatives exhibited greater activity against three tested tumor cells (A549, KB, and KB-VIN) than 2, and induced cell cycle arrest in the G2/M phase. Moreover, SAR conclusions were first established for this series of compounds. Our study clearly identified a structural feature that should be retained for good activity and also a moiety that can tolerate various modifications and, thus, is ideal for further changes.

Graphical abstract: Design, synthesis and structure–activity relationships of (±)-isochaihulactone derivatives

Article information

Article type
Research Article
Submitted
21 Jun 2017
Accepted
15 Sep 2017
First published
12 Oct 2017

Med. Chem. Commun., 2017,8, 2040-2049

Design, synthesis and structure–activity relationships of (±)-isochaihulactone derivatives

Y. Zhao, P. Liu, K. Hsieh, P. Hsu, M. Goto, S. L. Morris-Natschke, H. Harn and K. Lee, Med. Chem. Commun., 2017, 8, 2040 DOI: 10.1039/C7MD00310B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements